CARE Checklist of information to include when writing a case report

BY-NC-ND

Topic	Item No	Checklist item description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title	1	The diagnosis or intervention of primary focus followed by the words “case report”	page1/line1	Title
Key Words	2	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report"	page 3/line 41	Key Words
Abstract (no references)	3a	Introduction: What is unique about this case and what does it add to the scientific literature?	page 3/line 28-29	Abstract
	3b	Main symptoms and/or important clinical findings	page 3/line 29-31	Abstract
	3c	The main diagnoses, therapeutic interventions, and outcomes	page 3/line 31-39	Abstract
	3d	Conclusion—What is the main “take-away” lesson(s) from this case?	page 3/line 39-40	Abstract
Introduction	4	One or two paragraphs summarizing why this case is unique **(may include references)**	page 4/line 51-56	Introduction/ paragraph1-2
Patient Information	5a	De-identified patient specific information	[illegible] ne 99-100	Case presentation
	5b	Primary concerns and symptoms of the patient	[illegible] ne 99-100	Case presentation
	5c	Medical, family, and psycho-social history including relevant genetic information	[illegible] 6/line 100-101	Case presentation
	5d	Relevant past interventions with outcomes	[illegible] 6/line 100-101	Case presentation
Clinical Findings	6	Describe significant physical examination (PE) and important clinical findings	[illegible] ne 99	Case presentation
Timeline	7	Historical and current information from this episode of care organized as a timeline	[illegible] ne 99-100	Case presentation
Diagnostic Assessment	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys).	page 4/line 67-70 and page [illegible]	Case presentation
	8b	Diagnostic challenges (such as access to testing, financial, or cultural)	page4/line 76-69	Case presentation
	8c	Diagnosis (including other diagnoses considered)	[illegible] 6/line 116-117	Case presentation
	8d	Prognosis (such as staging in oncology) where applicable	[illegible] ne 117	Case presentation
Therapeutic Intervention	9a	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)	[illegible] ne 101-102	Case presentation
	9b	Administration of therapeutic intervention (such as dosage, strength, duration)	page 6/line 118-120	Case presentation
	9c	Changes in therapeutic intervention (with rationale)	[illegible] to the guideline.	Case presentation

Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available)	page/line 97 and page/line 117	Case presentation
	10b	Important follow-up diagnostic and other test results	page/line 97 and page/line 117	Case presentation
	10c	Intervention adherence and tolerability (How was this assessed?)	page 5/line 97 and page 6/line 112	Case presentation
	10d	Adverse and unanticipated events	N/A	Case presentation
Discussion	11a	A scientific discussion of the strengths AND limitations associated with this case report	page 9-10/line 205-210	Discussion/paragraph 6
	11b	Discussion of the relevant medical literature **with references**	page 8/line 169-179	Discussion/paragraph 3
	11c	The scientific rationale for any conclusions (including assessment of possible causes)	page 8/line 168-179	Discussion/paragraph 3
	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion	page 9-10/line 201-210	Discussion/paragraph 6
Patient Perspective	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received	page 9/ line 191-200	Case presentation
Informed Consent	13	Did the patient give informed consent? Please provide if requested	**Yes** ☑	**No** ☐

Article information: https://dx.doi.org/10.21037/gs-21-591
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.